

Application No. 10/729,340

Amendment dated May 30, 2007

Reply to Final Office Action of March 9, 2007

Docket No. NY-LUD 5793-US1-CIR

RECEIVED
CENTRAL FAX CENTER

MAY 30 2007

AMENDMENTS TO THE SPECIFICATION

Page 1, paragraph [0001], please delete, and replace with the following:

-- [0001] This application is a continuation-in-part of abandoned application Serial No. 60/430,869, filed December 4, 2002, which is a continuation-in-part of application Serial No. 10/181,663, filed November 29, 2000 which is a continuation-in-part of application Serial No. 09/602,362, filed June 22, 2000, now U.S. Patent No. 6,911,529, which is a continuation in part of application Serial No. 09/451,739, filed November 30, 1999, now U.S. Patent No. 6,774,226, all of which are incorporated by reference in their entirety. --

Application No. 10/729,340

Amendment dated May 30, 2007

Reply to Final Office Action of March 9, 2007

Docket No.: NY-LUD 5793-US1-CIP

AMENDMENTS TO THE CLAIMSRECEIVED
CENTRAL FAX CENTER

MAY 30 2007

Claims 1-12. (Canceled)

Claim 13. (Previously presented) Isolated cancer associated antigen comprising the amino acid sequence encoded by SEQ ID NO: 1, 3, 4, 8, 15, 19, 22, 26 or 31.

Claims 14-57. (Canceled)

Claim 58. (Currently amended) A composition comprising at least one MHC binding peptide consisting of an amino acid sequence of from 8 to 25 amino acids which are present in consecutive order in the isolated cancer associated antigen of claim 13, wherein said amino acid sequence is identical to an amino acid sequence found in SEQ ID NO.: 31, and a pharmaceutically acceptable adjuvant.

Claim 59. (Original) The composition of claim 58, wherein said adjuvant is a saponin, a cytokine, or GM-CSF.

Claim 60. (Original) The composition of claim 58, comprising a plurality of MHC binding peptides.

Claims 61-84. (Canceled)

Claim 85. (Original) An isolated polypeptide comprising at least 9 consecutive amino acids set forth in SEQ ID NO: 5, 7, 16, 19, 23, 27, 30 or 32.

Claim 86. (Original) The isolated polypeptide of claim 85, comprising at least 9 consecutive amino acids set forth in SEQ ID NO: 23, 30 or 32.

Application No. 10/729,340
Amendment dated May 30, 2007
Reply to Final Office Action of March 9, 2007

Docket No. NY-LUD 5793-US1-CIP

Claims 87-91. (Canceled)

Claim 92. (Previously presented) An isolated cancer associated antigen comprising the amino acid sequence encoded by SEQ ID NO: 31.

Claims 93-114. (Canceled)

Claim 115. (Currently amended) An isolated peptide consisting of the amino acid sequence LLSHGAVIEV (amino acids 158-167 of SEQ ID NO: 32) or SLSKILDTV (amino acids 960-968 of SEQ ID NO: 32), or SLDQKLFQL (amino acids 1318-1326 of SEQ ID NO: 32).